RE:RE:RE:Status QuoHow much are you getting paid to post like a loser gojotv! everyday of the week? Your posts goes to show how badly you are performing when SP keeps sinking with some minor bumps upwards because a handful of retailers are showing some interest in this point in time. By the way, the stockmarket has already factored in all the information you been spewing since the SP drop and is in total disagreement. You want to know who's the real loser here? You will find him when you look in the mirror.
gojotv! wrote: You clearly know nothing of Tripp's background and past achievements to post such bass-ackeards gaslighting.
More lies from the bashers...
Do your DD StockscoutX wrote: I agree with your assessment of the situation for StageZero and what happened. If only there would be more realistic and neutral posts like the one you just posted, it would make for serious and interesting exchanges here. I am still interested in StageZero because I have a small position but enventually waiting to see at what SP range it will level off and have a potential to move upwards before thinking to increase again my position.
One way that StageZero could boost confidence is for the CEO to step aside and have a new CEO that is well connected which could take StageZero in a direction that is expected by shareholders. In essence work also for shareholder interest. The present CEO, in my opinion, shareholders interest doesn't register at all in his mind and he is not a team player. Furthermore, he lacks total business savvy to market and present StageZero to it's shareholders that was seen in the last CC. He is best at what he does in the medical field except being a business man.
capebretongirl wrote: I am long here and own a ton of shares, however reality is what it is.
The sp at the moment is trending down daily again approaching our most recent low - and on low volume.
Past experience has shown us that Q covid revenue doesn't move the needle very far - read: Q3 ,Q4 as they provide the most relevant comparison. Undoubtedly Q1 will be the largest quarter ever, probably $4-5 million. However, that doesn't mean we suddenly shoot to $1.00 and beyond - the market already knows today that Q1 will be huge but its clearly not baking any excitement into the sp. Check with Clarus.
The only way this goes forward to the areas we hope is if we see some good fresh news - affiliations/mergers/collaborations/marketing strategy on the Aristotle front as that is the future of this company and what we waited 20 years for. We were promised that the $ 7 million pp cash up and fresh covid revenue would lead to an aggressive marketing program - that should have been specific, immediate and planned for during the 3 month silence lapse we had - but it wasn't. Now, with the physican link requirement to Aristotle as a test, is it the intention of that marketing program to promote CARE and the AVRP program starting in July when CARE is purchased since Aristotle is embedded in it?? Will the marketing program in the interim simply entail the more frequent reposting of older news on social media read: Inkedin, FB, Twitter etc. and that was the strategy all along? Clearly, from here forward, the only catalyst for us will be fresh news as only that generates excitement. And that involves actual signings rather than optimistic rhetoric from the company.
The $473000 cancer intake for 2020 is the bright light in all this and I wish Tripp had talked about the source of that revenue during the CC as its our only non covid revenue and it makes sense that it should increase in 2021. This is the tidbit that provides support for any small optimism - lets face it, investors need only look at the tangible results a la Quarterly reports and determine at a glance if the talk measured up to the revenue - and the next few quarterly glances will either confirm or deny Tripp's optimism. One day, after the last covid dollar has been received, we will be left with one asset and that is Aristotle - yes the AVRP might generate related spin off income but that is uncertain.
The Clarus downgrade hurt - going from $4 to $1.25 is simply not good news for any stock and it can't be candy coated. Institutional buyers don't get excited seeing that type of downgrade and are less inclined to buy, leaving it to retail. Analyst forecasts can turn around in a hurry, however we need a credibility boost like a large workplace employer or the like to sign on as that would serve to validate Aristotle's merit - clearly Atkinson knows about the upcoming Q1 covid revenue but we still got the downgrade.
Something has to give here - we were led to believe there would be exciting corporate developments announced on the Aristotle front - time to bring them out.